Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(198 intermediate revisions by 11 users not shown)
Line 1: Line 1:
{| class="wikitable" style="margin:auto"
Ian Welcome!
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
 
*For assignments, please see the "Author" column below (highlighted blue).
 
*If empty (no name is present), please volunteer to create content for that disease!
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
 
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
 
__TOC__
 
<br />
{| class="wikitable sortable" style="margin:auto"
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
|-
|-
!Disease (5th Edition)!!Page Type!!Author (5th Edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Correlated Prior Author (4th Edition)
!Content Status (4th Edition)(Pending or Complete)
!Prior Content Status (4th Edition)(Pending or Complete)
!Date of Last Editor Review (4th Edition)
!Prior Date of Last Editor Review (4th Edition)
!Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
|
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)====
|
|
----<br />
----<br />
Line 15: Line 32:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
|4/8/24, email again in 9/29/25; Meenakshi confirmed om 9/30/25.
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 34: Line 65:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease||Zejuan Li
|10/3/2025
| ||Pending|| ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 41: Line 74:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||J . Reid||9/29/25|| || || ||FQR|| ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 48: Line 81:
|
|
|-
|-
|Chronic neutrophilic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Neutrophilic Leukemia (CNL)
|Chronic Neutrophilic Leukemia (CNL)
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
Line 55: Line 89:
|
|
|-
|-
|Chronic eosinophilic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||Daynna Wolff
|10/14/25|| || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|Chelsea D. Kramish; Daynna J.Wolff
Line 62: Line 97:
|
|
|-
|-
|Polycythaemia vera||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||
| || || || ||FQR|| ||
|Polycythemia Vera (PV)
|Polycythemia Vera (PV)
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
Line 69: Line 105:
|
|
|-
|-
|Essential thrombocythaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|10/1/25|| ||Pending|| ||FQR|| ||
|Essential Thrombocythemia (ET)
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 76: Line 113:
|
|
|-
|-
|Primary myelofibrosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Primary Myelofibrosis (PMF)
|Primary Myelofibrosis (PMF)
|T. Niroshi Senaratne, UCLA
|T. Niroshi Senaratne, UCLA
Line 83: Line 121:
|
|
|-
|-
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
| || || || ||FQR|| ||
|Juvenile Myelomonocytic Leukemia (JMML)
|Juvenile Myelomonocytic Leukemia (JMML)
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Line 94: Line 133:
|FQR has emailed SR several times, last 4/20/22
|FQR has emailed SR several times, last 4/20/22
|-
|-
|Myeloproliferative neoplasm, NOS||Disease|| || || || || ||FQR|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Thomas Lee, MD, PhD, University of California, Los Angeles
|Thomas Lee, MD, PhD, University of California, Los Angeles
Line 101: Line 157:
|
|
|-
|-
|Cutaneous mastocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Cutaneous Mastocytosis
|Cutaneous Mastocytosis
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
Line 108: Line 165:
|
|
|-
|-
|Systemic mastocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
|Systemic Mastocytosis
|Systemic Mastocytosis
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University  Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
|Complete
|Complete
|
|
|
|
|-
|-
|Mast cell sarcoma||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
| || || || ||FQR|| ||
|Mast Cell Sarcoma
|Mast Cell Sarcoma
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
Line 122: Line 180:
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
Line 129: Line 188:
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||
| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 136: Line 196:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease||Eric McGinnis (assigned to new 5th edition page - FQR please follow-up to confirm)|| || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) YES fqr 9/29/25|| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 143: Line 203:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 150: Line 210:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 157: Line 217:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with increased blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 164: Line 225:
|
|
|-
|-
|Childhood myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 171: Line 249:
|
|
|-
|-
|Childhood myelodysplastic neoplasm with increased blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 178: Line 257:
|
|
|-
|-
|Chronic myelomonocytic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Myelomonocytic Leukemia (CMML)
|Chronic Myelomonocytic Leukemia (CMML)
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 185: Line 265:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
| || || || ||FQR|| ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 192: Line 273:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
Line 199: Line 281:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
Line 206: Line 289:
|
|
|-
|-
|Acute promyelocytic leukaemia with PML::RARA fusion
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|Disease
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
Line 222: Line 306:
|
|
|-
|-
|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 238: Line 323:
|
|
|-
|-
|Acute myeloid leukaemia with CBFB::MYH11 fusion
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 254: Line 340:
|
|
|-
|-
|Acute myeloid leukaemia with DEK::NUP214 fusion
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 270: Line 356:
|
|
|-
|-
|Acute myeloid leukaemia with RBM15::MRTFA fusion
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Complete
|
|
|
|JH_MS
|JH_MS
Line 286: Line 388:
|
|
|-
|-
|Acute myeloid leukaemia with BCR::ABL1 fusion
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|
|Xinxiu Xu (trainee);
|
Malini Sathanoori, Ph.D.
|4/15/25
|
|
|
|
Line 302: Line 405:
|
|
|-
|-
|Acute myeloid leukaemia with KMT2A rearrangement
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 318: Line 422:
|
|
|-
|-
|Acute myeloid leukaemia with MECOM rearrangement
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|Disease
|Disease
|Gordana Raca MD PhD,
|9/8/25
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 334: Line 438:
|Need permission for figure? Update WHO?
|Need permission for figure? Update WHO?
|-
|-
|Acute myeloid leukaemia with NUP98 rearrangement
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|Disease
|Disease
|Eric McGinnis, MD;
Fatma Al-Bulushi (trannee)
|12/20/23
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 350: Line 455:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with NPM1 mutation
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
|Disease
|Disease
|
|
Line 359: Line 464:
|JH_MS
|JH_MS
|
|
|
|emailed request on 7/16/24. No response as of 9/7/25.
Prior author: Xinjie Xu, PhD, FACMG
 
Open to new author
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Xinjie Xu, PhD, FACMG
|Xinjie Xu, PhD, FACMG
|Complete
|Complete
|
|
|Add WHO reference
|Add WHO reference<br />
|-
|-
|Acute myeloid leukaemia with CEBPA mutation
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|Paul Defazio, MSc, Monash Health
|Xinxiu Xu (trainee);
|
Malini Sathanoori, Ph.D.
|4/15/25
|
|
|
|
Line 376: Line 485:
|
|
|
|
|
|Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA
|
|Paul Defazio, MSc, Monash Health
|
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia, myelodysplasia-related
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
|Disease
|Disease
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
|
|
|
|
|
Line 390: Line 499:
|
|
|JH_MS
|JH_MS
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
|Complete
|
|
|-
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|Disease
|
|
|
|
Line 395: Line 514:
|
|
|
|
|JH_MS
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with other defined genetic alterations
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
|Disease
|Disease
|
|
Line 407: Line 532:
|JH_MS
|JH_MS
|
|
|Prior author: Celeste Eno, PhD
Open to new author
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Complete
|
|
|
|
|
|
|
|
|-
|-
|Acute myeloid leukaemia with minimal differentiation
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|Disease
|Disease
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|
|Acute Myeloid Leukemia (AML) without Maturation
|
|Jennelle C. Hodge, PhD, FACMG
|
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia without maturation
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|Disease
|Disease
|Jennelle C. Hodge, PhD, FACMG
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Acute Myeloid Leukemia (AML) with Maturation
|Jennelle C. Hodge, PhD, FACMG
|Complete
|
|
|
|
|-
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|Disease
|Ashwini Yenamandra PhD FACMG
|5/1/24
|
|
|Pending
|
|
|JH_MS
|
|
|-
|Acute myeloid leukaemia with maturation
|Disease
|Jennelle C. Hodge, PhD, FACMG
|
|
|Acute Basophilic Leukemia
|Ashwini Yenamandra PhD FACMG
|Complete
|
|
|
|
|-
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
|Disease
|
|
|JH_MS
|
|
|
|
|
|
|
|
|JH_MS
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myelomonocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute basophilic leukaemia
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|
|
|
|
|
Line 471: Line 630:
|JH_MS
|JH_MS
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Monoblastic and Monocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|Disease
|Ashwini Yenamandra PhD FACMG
|5/1/24
|
|
|Pending
|
|
|JH_MS
|
|
|Pure Erythroid Leukemia
|Ashwini Yenamandra PhD FACMG
|Complete
|
|
|
|
|-
|-
|Acute myelomonocytic leukaemia
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
|Disease
|Disease
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR
|
|
|
|
|
Line 487: Line 662:
|JH_MS
|JH_MS
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Megakaryoblastic Leukemia (AMKL)
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|Disease
|Yalda Naeini
|6/11/24
|
|Pending
|
|JH_MS
|
|
|
|
|Myeloid Sarcoma
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
|Complete
|
|
|
|
|-
|-
|Acute monocytic leukaemia
|RESOLVE 4th edition AML-Related NON-WHO entities content
|Disease
|[[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3|Acute Myeloid Leukemia (AML) with Mutated FLT3]] + [[HAEM4:Acute Myeloid Leukemia (AML) with NUP214-ABL1|Acute Myeloid Leukemia (AML) with NUP214-ABL1]] + [[HAEM4:Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6|Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6]]
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
|ISSUE- FIX
 
 
Resolve Non-WHO entities
|
|
|
|
|
|
|
|
|
|JH_MS
|
|
|
|
Line 510: Line 704:
|
|
|-
|-
|Acute erythroid leukaemia
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|Rabail Aslam, MD (trainee);
|
Shashi Shetty, Ph.D.
|
|7/1/24
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Therapy-Related Myeloid Neoplasms
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
|Complete
|
|
|Check reference format
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|Disease
|Malini Sathanoori, Ph.D.
|12/6/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|Multiple pages including overview page ([[Myeloid Neoplasms with Germline Predisposition|Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)]]) and 6 disease pages ( [[HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation]], [[HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation]])
|See links from instructions on the 5th edition page
|Complete
|Most were re-reviewed by MS on 03/02/2021
|For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
|-
|-
|Acute megakaryoblastic leukaemia
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
|Disease
|Disease
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
|
|
|
|
|
Line 535: Line 762:
|JH_MS
|JH_MS
|
|
|
|Prior author:
|
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|Complete (all three pages)
|
|
|
|
|-
|-
|Myeloid sarcoma
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|Disease
|Disease
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|FQR
|
|
|
|
|
|
|
|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement
|Jay Alden, DO
|Complete
|
|
|
|
|-
|-
|Myeloid neoplasm post cytotoxic therapy
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|Disease
|Disease
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|FQR
|
|
|
|
|
|
|
|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement
|Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD
|Complete
|
|
|
|
|-
|-
|Myeloid neoplasms associated with germline predisposition
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|Disease
|Disease
|PENDING
|
|
|
|
|
|
|
|
|FQR
|
|
|JH_MS
|
|
|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
|Yanna Ding, MD PhD
|Complete
|
|
|
|
|-
|[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]]
|Disease
|ISSUE- FIX
Resolve Non-WHO entities
|
|
|
|
|
|
|
|
|-
|FQR
|Myeloid proliferations associated with Down syndrome
|Disease
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|
|
|
|
|Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with ETV6-JAK2|Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]])  + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with BCR-JAK2|Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]] )  - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff
|Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff
|Complete
|
|
|
|
|JH_MS
|-
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|Disease
|
|
|
|
Line 603: Line 844:
|
|
|
|
|FQR
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|Disease
|Disease
|Jay Alden, DO
|Mayuri Shende (trainee);
|
Scott Turner (mentor)<br />
|
|9/22/24
|
|
|Pending
|
|
|FQR
|FQR
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|Disease
|Rolando Garcia
|2/7/2025
|
|
|Pending
|
|
|FQR
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|FQR
|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1
|
|Tracy Tucker, PhD, FCCMG
|Complete
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|Pending
|
|JH_MS
|
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged
|Tracy Tucker, PhD, FCCMG
|Complete
|
|
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement
|[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]]
|Disease
|Disease
|Yanna Ding, MD PhD
|
|
|
|
|
|
|
|
|FQR
|
|
|JH_MS
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|Pending
|
|JH_MS
|
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
|Complete
|
|
|
|
|-
|-
|Myeloid/lymphoid neoplasm with JAK2 rearrangement
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|Disease
|Disease
|Jessica Snider, M.D. and Daynna J. Wolff, PhD
|PENDING
|
|
|
|
|
|
|
|
|FQR
|JH_MS
|
|
|emailed 5/1/24
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|Complete
|
|
|
|
|-
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|Disease
|Daynna Wolff, PhD
|5/9/24
|
|
|Pending
|
|
|JH_MS
|
|
|Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|PENDING
|
|
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FLT3 rearrangement
|[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]]
|Disease
|Disease
|
|
Line 677: Line 1,006:
|
|
|
|
|FQR
|JH_MS
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|Acute Undifferentiated Leukemia
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|Complete
|
|
|Check reference format
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion
|Disease
|
|
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)====
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|FQR
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes
|Disease
|
|
|
----<br />
|
|
----<br />
|
|
|
----<br />
|FQR
|-
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
|Disease
|
|
|
|
Line 715: Line 1,086:
|
|
|
|
|Greg Corboy (GC)
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|Daynna Wolff
|5/3/2025
|8/3/2025
|Pending
|
|
|GC
|
|
|
|
|Blastic Plasmacytoid Dendritic Cell Neoplasm
|Hao Liu, MD and Daynna J. Wolff, PhD
|Complete
|
|
|JH_MS
|Previously within myeloid section under JH/MS editors
|-
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|Disease
|
|
|
|
Line 731: Line 1,118:
|
|
|
|
|GC
|
|
|
|
|Langerhans Cell Histiocytosis
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|-
|-
|Mixed-phenotype acute leukaemia with KMT2A rearrangement
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|
|
|
|
|JH_MS
|
|
|
|
Line 747: Line 1,134:
|
|
|
|
|GC
|
|
|
|
|Langerhans Cell Sarcoma
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|-
|-
|Acute leukaemia of ambiguous lineage with other defined genetic alterations
|[[HAEM5:Indeterminate dendritic cell tumour|Indeterminate dendritic cell tumour]]
|Disease
|Disease
|
|
Line 757: Line 1,150:
|
|
|
|
|JH_MS
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|Disease
|Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia, B/myeloid
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|Disease
|Disease
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
|Mayuri Shende (trainee);
|
Scott Turner (mentor)<br />
|
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|
|Pending
|JH_MS
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia, T/myeloid
|[[HAEM5:ALK-positive histiocytosis|ALK-positive histiocytosis]]
|Disease
|Disease
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|
|
|
|
|JH_MS
|
|
|
|
Line 795: Line 1,233:
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia, rare types
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
|Disease
|Disease
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|
|
|
|
|
|
|
|
|JH_MS
|
|
|GC
|
|
|
|
|Histiocytic Sarcoma
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|Complete
|10/01/2021
|Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply.
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|
|
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Acute leukaemia of ambiguous lineage, NOS
|Disease
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|JH_MS
----<br />
|
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Acute undifferentiated leukaemia
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|Disease
|Disease
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025 Emailed 9/4/2025 to remind
|
|Pending
|
|JH_MS
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|Disease
|Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)
|[[HAEM5:Unicentric Castleman disease|Unicentric Castleman disease]]
|Disease
|
|
----<br />
|
|
----<br />
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Idiopathic multicentric Castleman disease|Idiopathic multicentric Castleman disease]]
|Disease
|
|
|
|
Line 861: Line 1,360:
|
|
|
|
|GC
|
|
|
|
|-
|NEW (No Prior)
|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
|Disease
|Disease
|
|
Line 871: Line 1,376:
|
|
|
|
|Greg Corboy (GC)
|GC
|
|
|
|
|Multicentric Castleman Disease
|Sudha Arumugam, MD
|Complete
|01/24/2022. Emailed 5/1/2025, no response
|Date completed by author: 01/24/2022
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|To be covered in B-ALL, NOS
|
|
|
|
|
|
|
|
|Sumi Kitahara (SK)
|
|
|-
|Blastic plasmacytoid dendritic cell neoplasm
|Disease
|Hao Liu, MD and Daynna J. Wolff, PhD
|
|
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified
|Holli Drendel
|PENDING
|
|
|
|
|
|-
|GC
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|Disease
|Miguel Gonzalez Mancera, MD
|
|
|
|
|Complete (pending review by SK)
|
|
|SK
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|PENDING
|
|
|
|
|-
|-
|Langerhans cell histiocytosis
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|Disease
|Disease
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Miguel Gonzalez Mancera, MD
|
|
|
|
|Complete (pending review by SK)
|
|
|SK
|
|
|GC
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|Complete
|
|
|
|
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|Disease
|Holli Drendel, PhD
|Nov 11/2025
|
|
|Pending
|
|
|SK
|
|
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli]
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|?Complete
|
|
|
|
|-
|-
|Langerhans cell sarcoma
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|Disease
|Disease
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Karin Miller, MD
|10/9/2025
|12/5/2025
|
|
|
|
|SK
|
|
|
|
|GC
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
|
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|PENDING
|
|
|
|
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Mark G. Evans, MD
|10/1/2025
|11/17/2025
|Complete (pending review by SK)
|11/8/2025
|SK
|Pending
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
|Complete
|
|
|
|
|-
|-
|Indeterminate dendritic cell tumour
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|Disease
|Disease
|Gokce A. Toruner, MD, PhD
|10/9/2025
|11/5/2025
|Pending
|
|
|SK
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged
|Yassmine Akkari  Nicolas Millan
|PENDING
|
|
|
|
|GC
|-
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|Disease
|Gokce A. Toruner, MD, PhD
|10/8/2025
|12/1/2025
|Pending
|
|
|SK
|
|
|
|
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|PENDING
|
|
|
|
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|Disease
|Lei Zhang, PhD
Michelle Fan (trainee)
|10/10/2025
|12/22/2025
|Pending
|
|
|SK
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Interdigitating dendritic cell sarcoma
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera, MD
|10/1/2025
|
|
|Pending
|
|
|SK
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|PENDING
|
|
|GC
|
|
|-
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|Disease
|Miguel Gonzalez Mancera, MD
|10/1/2025
|
|
|Pending
|
|
|SK
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|PENDING
|
|
|
|
|-
|-
|Juvenile xanthogranuloma
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|Disease
|Disease
|Aiko Otsubo, PhD
|10/10/2025
|11/24/2025
|Complete (pending SK review)
|11/11/2025
|SK
|Pending
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|Disease
|Lei Zhang, PhD
|10/10/2025
|12/22/2025
|Pending
|
|
|SK
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease
|Karin Miller, MD
|10/9/2025
|11/24/2025
|Pending
|
|
|GC
|SK
|
|
|
|
Line 976: Line 1,626:
|
|
|-
|-
|Erdheim-Chester disease
!Disease (5th Edition)
|Disease
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
 
 
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
 
 
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
 
 
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE- FIX
 
 
Resolve Non-WHO entities
|
|
|
|
|GC
|
|
|
|
Line 990: Line 1,671:
|
|
|
|
|ISSUE - FIX
|
|
|-
|Rosai-Dorfman Disease
|Disease
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG)
| ||
|Monoclonal B-cell Lymphocytosis
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|PENDING, 4/30/2024
|
|
|Assigned 12/19/2022 with completion date of 1/19/2023
|-
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa,
Renee Eigsti, MD, Pathology Services of Kalamazoo,
Honey Reddi, PhD, Belay Diagnostics
| || ||Complete|| ||SG|| ||
|Already converted to 5th edition
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
|
|
|
|
|GC
|
|
|-
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee);
Shivani Golem
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia
|Snehal Patel, MD, PhD
|Pending WHO 5th e. July 2024
|
|
|
|
|-
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi
|4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Marginal Zone Lymphoma
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|-
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|-
|-
|ALK-positive histiocytosis
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
|Disease
|Disease
|
|
Line 1,015: Line 1,745:
|
|
|
|
|GC
|SG
|
|
|Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia Variant
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|-
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|Disease
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|SG
|
|
|Email sent to request to update 2024
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|Complete
|4/12/2023 by FQR
|
|
|-
|-
|Histiocytic sarcoma
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|Disease
|Disease
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|GC
|SG
|
|
|Email sent to request to update 2024
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)
|Complete
|4/12/23 by FQR
|
|
|-
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|Disease
|Molly Walkenhorst
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|SG
|
|
|
|
|NEW (No Prior)
|Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|Disease
|Andrew Ly
|
|
----<br />
|9/4/2025 sent E-mail reminder
|
----<br />
|
|
|
|
|SG
|
|
|
|
|Nodal Marginal Zone Lymphoma
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|Complete
|5/28/2021
|
|
|-
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
|Disease
|
|
|
|
Line 1,055: Line 1,843:
|
|
|
|
|SG
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric Nodal Marginal Zone Lymphoma
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|Complete; Need new author to update latest content. Primary author cannot update the page.
|11/11/2020
|
|
|-
|-
|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma
|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|
|SG
|
|
|
|In Situ Follicular Neoplasia
|Rachel D. Burnside, PhD, MBA, FACMGG
|Pending
|
|
|
|
|-
|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|
|
|SG
|
|
|GC
|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity
|(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma
|(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|Pending
|
|
|
|
|-
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|
|
|
|
|SG
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric-Type Follicular Lymphoma
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|Complete; Need new author to update latest content. Primary author  cannot update the page.
|8/16/2020
|
|
|-
|-
|IgG4-related disease
|[[HAEM5:Duodenal-type follicular lymphoma|Duodenal-type follicular lymphoma]]
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/
|Pending
|
|
|SG
|
|
|
|
|Duodenal-Type Follicular Lymphoma
|No prior content
|
|
|
|
|GC
|
|
|-
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|Disease
|Linlin Gao
|
|
|9/4/2025 Sent E-mail to remind
|
|
|
|
|SG
|
|
|
|
|Primary Cutaneous Follicle Centre Lymphoma
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|Complete
|09/10/2022
|
|
|-
|-
|Unicentric Castleman disease
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|Disease
|Disease
|
|
Line 1,097: Line 1,939:
|
|
|
|
|GC
|SG
|
|
|
|
|In Situ Mantle Cell Neoplasia
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|Complete
|7/26/2022
|
|
|-
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
|Disease
|PENDING
|
|
|9/4/2025 set E-mail reminder
|
|
|
|
|SG
|
|
|
|Mantle Cell Lymphoma
|Mahsa Khanlari, MD and  Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|Pending
|
|Target completion date 8/15/20
|-
|-
|Idiopathic multicentric Castleman disease
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|Disease
|Disease
|Farhan Sami
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|SG
|
|
|
|
|GC
|NEW (No Prior)
|
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|Disease
|Farhan Sami
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|SG
|
|
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|Pending
|
|
|Requested to update 14022022
|-
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|Complete
|24/02/2022
|
|
|-
|-
|KSHV/HHV8-associated multicentric Castleman disease
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||
|Disease
| || || || ||GC|| ||
|Sudha Arumugam, MD
|ALK-Positive Large B-cell Lymphoma
|
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|
|
|
|GC
|
|
|
|
|
|
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|-
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||
| || || || ||GC|| ||
|Large B-cell Lymphoma with IRF4 Rearrangement
|Afia Hasnain, MBBS, PhD
|Complete
|5/26/2021. Emailed 5/7//2025, no reply
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||
|Disease
| || || || ||GC|| ||
|
|Burkitt-Like Lymphoma with 11q Aberration
|
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|
|Complete
|
|27/01/2022  Emailed 5/7//2025, no reply
|
|Holli Drendel (HD)
|
|
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy
|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| ||
|Disease
|NEW (No Prior)
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|HD
|
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee);
|Disease
Andrew Siref as mentor
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|3/22/24|| ||Pending|| ||GC|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|HD
|NEW (No Prior)
|
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with iAMP21
|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| ||
|Disease
|NEW (No Prior)
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|-
|HD
!Disease (5th Edition)
|
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
|
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||
| || || || ||GC|| ||
|Plasmablastic Lymphoma
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Complete
|28/03/2022
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|Disease
|6/28/2025
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| ||
|
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|
|(1) Pending + (2) Complete
|
|(1) Not ready + (2) 03/28/22
|HD
|For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
|-
|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025
|8/6/2025 Emailed 9/4/2025 to remind
| || ||GC|| ||
|Intravascular Large B-cell Lymphoma
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
|Complete
|9/1/22
|Emailed 28/3/2022 for progress update
|-
|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Complete
|16/11/2021 Emailed 5/6/2025, no reply
|
|
|-
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||
| || || || ||GC|| ||
|Burkitt Lymphoma
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Complete
|28/06/2021 Emailed 5/6/2025, no reply
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
|
|
|
|
Line 1,218: Line 2,221:
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
|Disease
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
|Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine
| || || || ||GC|| ||
|Polymorphic Post-Transplant Lymphoproliferative Disorders
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
|Completed
|26/4/2022
|
|
|-
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
|
|
|
|
|
|
|HD
|
|
|
|
|-
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
|
|
|
|
Line 1,234: Line 2,251:
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu
|5/7/2025
|8/7/2025 Reminder email sent 9/4/2025|| ||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
|Pending + Completed (03/21/22)
|Not completed for checking (1, 3 and 4) + 03/21/22 (2)
|
|-
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
|Disease
|Disease
|Yassmine Akkari  Nicolas Millan
|
|
|
|
|HD
|
|
|
|
Line 1,247: Line 2,293:
|
|
|
|
|SG
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|Disease
|NEW (No Prior)
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|-
|HD
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||
| || || || ||SG
| ||
|Primary Amyloidosis
|Heather E. Williams, PhD, MS, PgD, ErCLG
|?PENDING<br />
|
|
|
|
|-
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||
| || || || ||SG
| ||
|Light Chain and Heavy Chain Deposition Disease
|Chen Yang, MD, PhD, University of Michigan
|Complete
|10/15/2022
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
|Disease
| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|HD
|-
|
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||
|
| || || || ||SG
| ||
|Gamma Heavy Chain Disease
|Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA
|Complete
|5/26/2021
|
|
|-
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||
| || || ||
|SG
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
Zhenya Tang
|4/14/25||7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang
|Pending|| ||SG
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
|Pending
|
|
|
|
|-
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
| ||9/4/2025 E-mail sent to Dr. Senaratne
| ||
|SG
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
|(1) POEMS Syndrome + (2) TEMPI Syndrome
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
|?PENDING
|
|
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
|Disease (5th Edition)
|Disease
|Page Type
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
|Date Assigned to Author (5th Edition)
|Target Completion Date (5th Edition)
|Content Status (5th Edition) (Pending or Complete)
|Date Completed by Author (5th Edition)
|Associate Editor
|Date of Last Editor Review (5th Edition)
|Notes (5th Edition)
|Correlated Prior Disease Name (4th Edition)
|Correlated Prior Author (4th Edition)
|Prior Content Status (4th Edition) (Pending or Complete)
|Prior Date of Last Editor Review (4th Edition)
|Prior Notes (4th Edition)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
| colspan="15" |
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|-
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK)
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee);
Karin Miller, MD
|3/25/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
|Disease
|Fei Yang, MD
|
|
|
|
|
|
|
|
|HD
|SK
|
|
|
|
|
|
|
|Early T-Cell Precursor Lymphoblastic Leukemia
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|Pending
|
|
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|Disease
|Disease
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|Parastou Tizro, MD;
Celeste Eno, PhD; Sumire Kitahara, MD
|9/23/2025
|11/4/2025
|'''Complete'''
|11/4/2025
|SK
|11/6/2025
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
Michelle Don, MD, MS
|9/24/2025
|12/9/2025
|Pending
| ||SK|| ||
|T-cell Large Granular Lymphocytic Leukemia
|Michelle Don, MD, MS
|Pending
|
|
|
|
|
|-
|HD
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
|
Michelle Don, MD, MS
|9/24/2025
|12/9/2025
|'''Complete'''
| 12/17/2025||SK|| 1/6/2026||
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Pending
|
|
|
|
|-
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||Sumire Kitahara, MD
|9/23/2025
|11/30/2025
|Pending
| ||SK|| ||
|Adult T-cell Leukemia/Lymphoma
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
|?Pending
|
|
|
|
|-
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|follow-up needed
| || ||SK|| ||
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Pending
|
|
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD
|Disease
|10/15/2025||1/19/2026
|
|Pending
|
| ||SK|| ||
|
|Aggressive NK-cell Leukemia
|
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|
|?Pending
|HD
|
|
|
|
|
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations
!Disease (5th Edition)
|Disease
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
|
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
|HD
!Associate Editor
|
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD
|1/6/2026
| 2/3/2026||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee);
 
Andrew Siref, MD
|10/14/2025
|11/24/2025
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|follow-up needed|| || ||SK|| ||
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Pending
|
|
|
|
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024
|follow-up needed
|
|
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024||follow-up needed
|
|
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|Pending
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma, NOS
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD
|Disease
Katelyn Swanson, DO (trainee)
|
|11/19/2025
|
|12/19/2025
|
|'''Complete'''
|
| 1/6/2026||SK|| 1/6/2026||
|
|NEW (No Prior)
|HD
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|-
|
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee);
|
Sumire Kitahara, MD
|
|6/30/2024
|11/9/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee);
| ||
 
|
Andrew Siref, MD
|
|10/14/2025||11/24/2025
|
|'''Complete'''
|
| 12/29/2025||SK|| 1/6/2026||
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
| || || || ||SK|| ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|
|
|-
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
|10/14/2025
| ||Pending|| ||SK|| ||
|Enteropathy-Associated T-cell Lymphoma
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
|Complete
|1/21/2021
|
|
|-
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
|10/14/2025
| ||Pending|| ||SK|| ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|
|
|-
|-
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
|
| || || || ||SK|| ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Derick Okwan MD, PhD (Stanford)  Sumire Kitahara MD (Cedars-Sinai)
|Complete
|9/26/2022
|
|
|-
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
Michelle Don, MD, MS
|9/24/2025
|11/9/2025
|'''Complete'''
|12/17/2025
|SK||1/6/2026||
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Complete
|1/21/2021
|
|
|-
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
|6/6/24|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Miguel Gonzalez Mancera, MD
Sumire Kitahara, MD
Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|-
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
|6/6/24|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|-
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|
|9/22/2025
|1/1/2026
|Pending|| ||SK|| ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
|Pending
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|follow-up needed
| || ||SK|| ||prior authors not available
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Pending
|
|
|
|
|-
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|
|follow-up needed
|
| || ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
|Disease
| || || || ||SK|| ||
|*Snehal Patel, MD, PhD
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|
|Pending
|
|
|SG
|
|
|
|
|
|
|
|
|
|-
|-
|Lymphoplasmacytic lymphoma
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|Disease
|10/14/2025
|Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|12/3/2025
|
|Pending
|
| ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|SG
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|
|
|
|
|-
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
|Disease
Andrew Siref, MD
|
|10/14/2025|| ||Pending|| ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|SG
|NEW (No Prior)
|
|
|
|
|
|
|
|-
|-
|Primary cutaneous marginal zone lymphoma
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD
|Disease
|1/6/2026
| 2/3/2026||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
| 11/17/2025||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
| 11/17/2025||Pending
| ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Complete
|11/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|
|
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)====
|
|
----<br />
|
|
----<br />
|
|
|SG
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Nodal marginal zone lymphoma
|Disease
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|
|
|
|
|SG
|
|
|
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Paediatric nodal marginal zone lymphoma
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
|Disease
|Disease
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|GC
|
|
|
|
|Follicular Dendritic Cell Sarcoma
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|?Pending
|
|
|
|
|-
|-
|In situ follicular B-cell neoplasm
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|
|
|
|
|
|
|SG
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
|Disease
|
|
|
|
|
|
|
|
|-
|Follicular lymphoma
|Disease
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|
|
|GC
|
|
|
|
|
|NEW (No Prior)
|SG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
|Disease
|
|
|
|
Line 1,523: Line 2,985:
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Paediatric-type follicular lymphoma
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
|Disease
|Disease
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|
|
|
|
|SG
|
|
|
|
Line 1,539: Line 3,001:
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Duodenal-type follicular lymphoma
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
|Disease
|Disease
|
|
Line 1,549: Line 3,017:
|
|
|
|
|SG
|GC
|
|
|
|
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous follicle centre lymphoma
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
|Disease
|Disease
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|
|
|
|
|SG
|
|
|
|
Line 1,571: Line 3,033:
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|In situ mantle cell neoplasm
|Disease
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|
|
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)====
|
|
----<br />
|
|
----<br />
|
|
|SG
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Mantle cell lymphoma
|Disease
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|
|
|
|
|SG
|
|
|
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Leukaemic non-nodal mantle cell lymphoma
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|Disease
|N/A||N/A
|<br />
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|SG
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|-
|
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Transformations of indolent B-cell lymphomas
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A
|Disease
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|SG
|
|
|
|
|
|
|
|-
|-
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|
|
|
|
|
|-
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
|
|
|
|
|
|-
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
|
|
|
|
|
|-
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
|
|
|
|
|
|-
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
|
|
|
|
|
|-
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|
|
|
|
|
|-
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|
|
|
|
|
|-
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
|
|
|
|
|
|-
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
|
|
|
|
|
|-
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
|
|
|
|
|
|-
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
|
|
|
|
|
|-
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
|-
|Cold agglutinin disease
|Disease
|
|
|
|
|
|SG
|
|
|
|
|
|
|
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|
|
|
|
|
|-
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|
|
|
|
|
|-
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
| ||
|
|
|
|
|
|-
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
| ||
|
|
|
|
|
|-
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
| ||
|
|
|
|
|
|-
|Mu heavy chain disease||Disease|| || || || || ||SG
| ||
|
|
|
|
|
|-
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
| ||
|
|
|
|
|
|-
|Alpha heavy chain disease||Disease|| || || || || ||SG
| ||
|
|
|
|
|
|-
|Plasmacytoma||Disease|| || || || || ||SG
| ||
|
|
|
|
|
|-
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
| ||
|
|
|
|
|
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
| ||
|
|
|
|
|
|-
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
| ||
|
|
|
|
|
|-
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
|
|
|
|
|
|-
|Early T-precursor lymphoblastic leukaemia / lymphoma
|Disease
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|
|
|
|
|HD
|
|
|
|
|
|
|
|-
|T-prolymphocytic leukaemia
|Disease
|
|
|
|
|
|SK
|
|
|
|
|
|
|
|-
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|
|
|
|
|
|-
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
|
|
|
|
|
|-
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
|
|
|
|
|
|-
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
|
|
|
|
|
|-
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|
|
|
|
|
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
|
|
|
|
|
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
|
|
|
|
|
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
|
|
|
|
|
|-
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
|
|
|
|
|
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
|
|
|
|
|
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Follicular dendritic cell sarcoma
|Disease
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|EBV-positive inflammatory follicular dendritic cell sarcoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Fibroblastic reticular cell tumour
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Intranodal palisaded myofibroblastoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Littoral cell angioma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Splenic hamartoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Sclerosing angiomatoid nodular transformation (SANT) of spleen
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|Bloom syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|RASopathies||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|}
|}
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"